Literature DB >> 21686640

Concurrent primary biliary cirrhosis and autoimmune hepatitis presenting as subfulminant hepatic failure.

Jason Ken Hou1, M Eric Gershwin, Linda K Green, Boris Yoffe.   

Abstract

Primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) overlap syndrome may be found in a significant percentage of patients with either PBC or AIH. However, it is conceivable that most cases of PBC-AIH overlap syndrome are a concurrent manifestation of both diseases which therefore requires treatment of both disease entities. While most cases are found in asymptomatic patients or in patients who have been previously diagnosed with PBC, our patient presented with concurrent PBC and AIH resulting in subfulminant liver failure that responded to treatment with prednisone and ursodeoxycholic acid (UDCA). Extended 4-year follow-up and treatment with UDCA confirmed the diagnosis of PBC and demonstrated serological resolution of AIH.

Entities:  

Year:  2009        PMID: 21686640      PMCID: PMC3028526          DOI: 10.1136/bcr.08.2008.0767

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization.

Authors:  Patrick S C Leung; Ogyi Park; Koichi Tsuneyama; Mark J Kurth; Kit S Lam; Aftab A Ansari; Ross L Coppel; M Eric Gershwin
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis.

Authors:  Roman Rieger; Patrick S C Leung; Melissa R Jeddeloh; Mark J Kurth; Michael H Nantz; Kit S Lam; Daniel Barsky; Aftab A Ansari; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  J Autoimmun       Date:  2006-07-28       Impact factor: 7.094

3.  Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.

Authors:  A W Lohse; K H zum Büschenfelde; B Franz; S Kanzler; G Gerken; H P Dienes
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure.

Authors:  E Kayacetin; S Köklü; T Temuçin
Journal:  Dig Liver Dis       Date:  2004-06       Impact factor: 4.088

5.  A 38-year-old African-American woman with an unusually rapid progression of "Primary Biliary Cirrhosis": a missed opportunity!

Authors:  Dirk J van Leeuwen; Gagan Sood; Dino Ferrante; Audrey J Lazenby; Marty J Sellers
Journal:  Semin Liver Dis       Date:  2002-11       Impact factor: 6.115

Review 6.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.

Authors:  O Chazouillères; D Wendum; L Serfaty; S Montembault; O Rosmorduc; R Poupon
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

Review 8.  The X and why of xenobiotics in primary biliary cirrhosis.

Authors:  Roman Rieger; M Eric Gershwin
Journal:  J Autoimmun       Date:  2007-03-23       Impact factor: 7.094

9.  Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome.

Authors:  Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Satoshi Saitoh; Akihito Tsubota; Fumitaka Suzuki; Masahiro Kobayashi; Norio Akuta; Takashi Someya; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

10.  Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease.

Authors:  Liana Gheorghe; Speranta Iacob; Cristian Gheorghe; Razvan Iacob; Iulia Simionov; Roxana Vadan; Gabriel Becheanu; Iuliana Parvulescu; Cristina Toader
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.